Genscript Biotech (HK:1548) has released an update.
Genscript Biotech Corporation has announced that it will engage with a U.S. congressional committee after receiving a letter seeking information about the company, clarifying that no accusations of wrongdoing have been made. The company, listed on the Hong Kong Stock Exchange, commits to keeping shareholders informed and advises investors to be cautious. The situation is being closely monitored, and developments will be communicated in compliance with regulatory requirements.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.